You invest in healthcare stocks without picking a loser by spreading your money across the sector through a low-cost fund instead of betting on one company, then checking what's actually inside that fund before you trust the word "diversified." Healthcare is one of the few sectors where even broad exposure carries concentrated risk, so the real skill is knowing where that risk hides. The healthcare sector runs on a mix of steady cash generators — hospitals, insurers, device makers — and binary long shots like early-stage drug developers, whose fortunes can swing on a single regulatory decision. Below is how to size up both ends of that spectrum before you commit real money.
Table of Contents
- Start With a Fund, Not a Single Stock
- Check What's Actually Inside That "Diversified" Fund
- Why One Company's Bad News Can Sink a Whole Subsector
- The Biggest Landmine: Betting on a Single Drug or Biotech
- A Quick Checklist Before You Buy
Start With a Fund, Not a Single Stock
The simplest way to avoid picking a loser is to not pick one stock at all. XLV, the Health Care Select Sector SPDR Fund, is the largest healthcare-sector exchange-traded fund and charges a 0.08% expense ratio — a small enough fee that it barely dents returns. It posted a 10.3% annualized return over the trailing 10 years as of July 2, 2026, giving investors exposure to the whole sector's growth without having to guess which individual company would deliver it.
That approach matters more in healthcare than in most sectors, because the industry mixes businesses with wildly different risk profiles under one roof: insurers, hospital chains, device manufacturers, and biotech firms whose value depends on a single drug trial succeeding. A fund spreads your bet across all of them at once, so no single company's bad quarter can wipe out your position. This doesn't mean a healthcare fund is risk-free or immune to downturns — the whole sector can fall together on policy news. But it removes the specific risk of guessing wrong on one name, which is the mistake most new sector investors make first.
Check What's Actually Inside That "Diversified" Fund
Buying a fund isn't automatically diversification. ETF Central's fund data shows that even XLV, as of a June 5, 2026 snapshot, held 58.8% of its assets in its top 10 companies — and Eli Lilly alone accounted for 14.34% of the fund.
That means a fund marketed as covering an entire sector can still rise or fall largely on the fortunes of one or two giant companies. Before buying any "diversified" healthcare fund, look up its top holdings and their combined weight. If one or two names make up more than a quarter of the fund, you're carrying meaningful single-company risk even though you technically own dozens of stocks.
- Pull the fund's current holdings list from the provider's website or a fund-data site.
- Add up the weight of the top five holdings.
- If that total tops 40-50%, treat the fund's risk more like a handful of stocks than a broad basket.
Why One Company's Bad News Can Sink a Whole Subsector
Concentration risk isn't theoretical. UnitedHealth Group shares fell about 18% year-to-date by late March 2026, on top of a 35% decline in 2025, after a near-flat Medicare Advantage payment update undercut the company's revenue assumptions. The company had already guided to 2026 revenue of "greater than" $439 billion — about a 2% drop from the prior year, its first annual revenue contraction since the late 1980s. The damage didn't stay contained to one stock.
In the same trading session, Humana shares fell more than 20%, showing that a single regulatory shock to one insurer can drag an entire subsector — managed care, in this case — down together. If your healthcare exposure leans heavily on insurers, a policy change aimed at just one company can still hit your whole position. This is the clearest argument for spreading exposure across subsectors, not just across companies. Insurers, pharmaceutical makers, device companies, and providers each respond to different pressures, so a policy shock to one group doesn't automatically spread to the others.
The Biggest Landmine: Betting on a Single Drug or Biotech
If you're drawn to individual biotech stocks for their upside potential, understand the odds first. An MIT analysis found that only about 14% of drugs entering clinical trials eventually win FDA approval, with the rate ranging from 33.4% for infectious-disease vaccines down to 3.4% for investigational cancer treatments.
A company whose stock price depends on one drug reaching approval is making a bet that fails far more often than it succeeds. This is why single-biotech positions behave less like typical stock investments and more like options: binary outcomes where most of the value depends on one event. If you want exposure to that upside without the binary risk of one trial result, a basket of several smaller biotech names — or a biotech-focused fund — spreads the failure risk across many shots instead of resting on one.
- Treat any pre-revenue biotech stock as a high-risk bet sized accordingly, not a core holding.
- Favor companies with an approved product generating revenue over those relying entirely on pipeline results.
- If a single trial readout could move the stock more than 30% in either direction, size the position so that swing wouldn't meaningfully hurt your overall portfolio.
A Quick Checklist Before You Buy
Pulling the sections above together, a few checks separate a reasoned healthcare position from a guess: None of this guarantees a winner. But it replaces blind stock-picking with a process that accounts for where healthcare's real risks sit — concentration inside funds, policy shocks to whole subsectors, and binary outcomes in individual biotech names.
- Decide whether you want sector-wide exposure or a single-company bet, and size the position accordingly — a fund for the former, a small slice of your portfolio for the latter.
- Look up the fund's top-10 concentration before assuming "diversified" means spread evenly.
- Ask what regulatory lever — drug pricing, Medicare rates, FDA approval — could move the stock or fund you're considering, since healthcare is unusually policy-sensitive.
- For any single stock, check whether its revenue depends on one product, one payer program, or one pending decision.